November 04th, 2023

On Wednesday, November 8, several notable companies are slated to disclose their financial performance, including: The Walt Disney Company (NYSE: DIS), a leading entertainment conglomerate, will present its fiscal full-year and fourth-quarter 2023. Read more

August 05th, 2023

Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) have received U.S. Food and Drug Administration (FDA) approval for ZURZUVAE (zuranolone) 50 mg, offering a groundbreaking 14-day oral treatment for postpartum depression (PPD) in a. Read more

July 23rd, 2023

On Tuesday, July 25, a lineup of notable companies is set to disclose their financial performance for the second quarter of 2023, including: Nucor Corporation (NYSE: NUE), a leading steel producer, will release its earnings before the market opens. Read more

July 07th, 2023

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) have received FDA approval for LEQEMBI (lecanemab-irmb), a groundbreaking treatment for Alzheimer's disease (AD), the most common type of dementia. LEQEMBI is the first approved therapy to demonstrate a . Read more

June 10th, 2023

Eisai and Biogen's (Nasdaq: BIIB) Alzheimer's drug candidate, LEQEMBI (lecanemab-irmb), received unanimous support from FDA PCNS panel based on Phase 3 Clarity AD trial data.  The committee acknowledged its clinical benefit, overall benefit-r. Read more